Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash from Investing Activities (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash from Investing Activities for 2 consecutive years, with $16.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 39.0% to $16.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.9 million through Dec 2025, up 621.73% year-over-year, with the annual reading at $58.9 million for FY2025, 621.73% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $16.3 million at Pyxis Oncology, up from $11.5 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $26.7 million in Q4 2024, with the low at -$18.5 million in Q1 2024.